TrxR: A Potential Drug Target and Biomarker for Thioredoxin Reductase

Target Name: Thioredoxin-disulfide reductase (TrxR)

NCBI ID: P6919

Thioredoxin-disulfide reductase (TrxR)

Other Name(s): Thioredoxin Reductase (nonspecified subtype)

TrxR: A Potential Drug Target and Biomarker for Thioredoxin Reductase

Introduction

Thioredoxin-disulfide reductase (TrxR) is a protein that plays a crucial role in the detoxification of thioredoxin, a toxic metabolite generated by cellular metabolism. Thioredoxin is toxic to cells because it can cause oxidative stress, DNA damage, and inflammation. Therefore, TrxR is a critical enzyme that protects cells from the harmful effects of thioredoxin. TrxR is a member of the thioredoxin reductase superfamily, which includes other enzymes that share a similar catalytic mechanism.

TrxR is a pseudogene that has been identified in various organisms, including bacteria, archaea, and eukaryotes. The human TrxR gene has been cloned and studied extensively, and several studies have characterized its function in different cellular processes.1-3

Drug Target Potential

TrxR is a drug target that can be inhibited with small molecules, making it an attractive target for drug development. The ability to selectively target TrxR while minimizing unintended effects on other cellular processes makes TrxR an attractive drug target for the development of new therapeutic agents. 4,5

TrxR is involved in multiple cellular processes, including cell signaling, DNA repair, and stress response. Therefore, inhibiting TrxR activity could have a wide range of potential therapeutic applications. For example, TrxR has been shown to be involved in the detoxification of thioredoxin, which is a potent oxidative stress agent.6,7 Therefore, inhibiting TrxR activity could be a promising strategy for treating thioredoxin-related diseases, such as thioredoxin-induced oxidative stress diseases and thioredoxin-mediated neurotoxicity.8

Biomarker Potential

TrxR is also a potential biomarker for various diseases, including cancer,9,10 neurodegenerative diseases,11,12 and inflammatory diseases. TrxR has been shown to be involved in multiple cellular processes that are relevant to these diseases, including cell signaling, DNA repair , and stress response. Therefore, TrxR levels or activity can be used as a biomarker for various diseases. For example, higher TrxR levels have been observed in various types of cancer, and inhibiting TrxR activity could be a promising strategy for targeting cancer cells. 13,14

TrxR is also involved in the detoxification of thioredoxin, which is a potent oxidative stress agent. Therefore, TrxR levels or activity can be used as a biomarker for thioredoxin-related diseases, such as thioredoxin-induced oxidative stress diseases.15,16

Conclusion

TrxR is a protein that plays a crucial role in the detoxification of thioredoxin, a toxic metabolite generated by cellular metabolism. TrxR is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and inflammatory diseases. The inhibition of TrxR activity could have a wide range of potential therapeutic applications. Further research is needed to fully understand the role of TrxR in different cellular processes and to develop new therapeutic agents that target TrxR.

Protein Name: Thioredoxin-disulfide Reductase (TrxR) (nonspecified Subtype)

The "Thioredoxin-disulfide reductase (TrxR) Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Thioredoxin-disulfide reductase (TrxR) comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets